Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AngloGold Ashanti Limited (AU) vs Novavax Inc (NVAX) Price & Performance

AngloGold Ashanti LimitedTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

AngloGold Ashanti Limited vs Novavax Inc — how do they compare? AngloGold Ashanti Limited trades at $98.33 (market cap $49.28B), while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: AngloGold Ashanti Limited is far larger — about 37.6× Novavax Inc's market cap, and AngloGold Ashanti Limited pays a 4.64% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

AUNVAX
Market Cap
$49.28B$1.31B
Sector
Basic MaterialsHealth
52-Week High
$128.26$11.19
52-Week Low
$52.15$6.22
Enterprise Value
$48.29B$889.30M
Dividend Yield
4.64%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AngloGold Ashanti Limited

AngloGold Ashanti (AU) trades at $97.25, up 1.07% today, with a bullish technical signal from moving averages but overbought RSI readings. Strong fundamentals include a 26.64% net margin for 2025, robust free cash flow growth, and a $2 billion buyback program. Recent Q2 2026 earnings beat expectations, though Q4 2025 and Q2 2026 were misses. Analyst consensus is bullish with a $120.33 price target, and institutional buying has been noted in recent filings.

Outlook remains positive due to high gold prices, production growth, and shareholder returns, but risks include operational disruptions, inflation pressures, and volatile gold markets. The stock offers value with a P/E of 13.06 and strong profitability, yet investors should monitor cost inflation and geopolitical factors affecting mining operations.

Novavax Inc

Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.

The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.

Returns comparison

Trailing returns across standard periods

About AngloGold Ashanti Limited

Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.

Read more on AU

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX